Working… Menu

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00652418
Recruitment Status : Completed
First Posted : April 3, 2008
Last Update Posted : October 14, 2013
Information provided by (Responsible Party):

Brief Summary:
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg regions) for visualization of arteries, evaluating 179 not assessable: caused by contrast media in the evaluation of structural abnormalities. Magnevist (SH L 451 A) was administered intravenously in a crossover design in patients with arterial disease in the abdominal to leg regions. The safety of the 0.2 mmol/kg dose was also assessed.

Condition or disease Intervention/treatment Phase
Magnetic Resonance Angiography Peripheral Vascular Diseases Peripheral Arterial Diseases Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of a Single Intravenous Injection of Magnevist (SH L 451 A) at 0.1 mmol/kg and 0.2 mmol/kg in Contrast-enhanced 3D-Magnetic Resonance Angiography in Patients With Arterial Disease in the Abdominal to Leg Regions in the Ability of Detecting of Vessel Abnormalities
Study Start Date : July 2004
Actual Primary Completion Date : October 2004
Actual Study Completion Date : October 2004

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Arm 1 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Magnevist at a dose of 0.1 mmol/kg

Experimental: Arm 2 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Magnevist at a dose of 0.2 mmol/kg

Primary Outcome Measures :
  1. Diagnostic ability [ Time Frame: MRI image in blinded read ]

Secondary Outcome Measures :
  1. Visibility [ Time Frame: MRI image in blinded read ]
  2. Diagnostic confidence [ Time Frame: MRI image in blinded read ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who are scheduled to undergo contrast-enhanced 3D-Magnetic Resonance Angiography

Exclusion Criteria:

  • Patients with an ankle brachial pressure index (ABPI) of 0.3 or less
  • Patients with allergy to contrast media
  • Patients with serious hepatic impairment
  • Patients with serious renal impairment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00652418

Layout table for location information
Hirosaki-shi, Aomori, Japan, 036-8563
Funai-gun, Kyoto, Japan, 629-0197
Hamamatsu-shi, Shizuoka, Japan, 431-3192
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00652418    
Other Study ID Numbers: 91396
First Posted: April 3, 2008    Key Record Dates
Last Update Posted: October 14, 2013
Last Verified: October 2013
Keywords provided by Bayer:
Magnetic Resonance Angiography
Meglumine gadopentetate
Determination of effective dose in MRA
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases